Clinical Trial Update: Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

View source ↗

Summary

Amivantamab (Rybrevant) has been approved for marketing for metastatic non-small cell lung cancer, and the update includes information on a pre-approval access …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Non-Small Cell Lung Cancer | Status: APPROVED_FOR_MARKETING